Truist Securities Maintains Hold on Biogen, Lowers Price Target to $189

Benzinga Newsdesk www.benzinga.com Negative 82.7%

Neg 82.7% Neu 0% Pos 0%

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:BIIB) with a Hold and lowers the price target from $193 to $189.